Methylphenidate
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Methylphenidate: Faciodigitogenital syndrome
One-Sentence Summary
Methylphenidate is a central nervous system stimulant originally used for attention deficit hyperactivity disorder (ADHD) and narcolepsy. The TxGNN model ranks faciodigitogenital syndrome as its top predicted new indication, but no clinical trials and no publications support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Faciodigitogenital syndrome |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, methylphenidate is a stimulant widely used for ADHD, and its efficacy in that condition is well established. The literature compiled for this report describes it as acting on the dopamine and norepinephrine transporters.
For faciodigitogenital syndrome, the data compiled for this report show no identifiable mechanistic link. The syndrome can involve ADHD-like features, which might loosely relate to methylphenidate’s dopaminergic and noradrenergic action, but this is speculative. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Other predicted indications (ranks 2-10)
| Rank | Predicted Indication | Score | Evidence Level | Assessment |
|---|---|---|---|---|
| 2 | Chondromyxoid fibroma | 0.9999 | L5 | No plausible mechanistic link; the score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence |
| 3 | Specific developmental disorder | 0.9999 | L5 | Overlaps with the approved ADHD use; evidence is indirect |
| 4 | Dysthymic disorder | 0.9911 | L5 | Plausible dopaminergic rationale; no direct testing in dysthymia |
Clinical Trial Evidence
Currently no related clinical trials registered for faciodigitogenital syndrome.
The trials below were retrieved for other predicted indications and are shown for context only.
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT00552266 | Phase 4 | Unknown | 30 | Methylphenidate in children and adolescents with ADHD and comorbid trichotillomania; not a trichotillomania-focused efficacy trial |
| NCT01393574 | Phase 4 | Unknown | 46 | Melatonin vs methylphenidate in children with ADHD and sleep-onset difficulties; main outcome is ADHD symptoms |
| NCT00989950 | Not applicable | Completed | 26 | Open-label study of individualised Daytrana patch wear-times and sleep in children with ADHD |
| NCT02638168 | Phase 4 | Terminated | 3 | Evening immediate-release methylphenidate and sleep in children with ADHD; terminated with 3 participants, so no usable evidence |
Literature Evidence
Currently no related literature available for faciodigitogenital syndrome.
The publications below were retrieved for other predicted indications, with trichotillomania, cerebellar ataxia and dysthymic disorder being the most relevant.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38858522 | 2024 | RCT | Int J Geriatr Psychiatry | Adverse events of methylphenidate for apathy in Alzheimer’s disease (ADMET2), including weight loss, vital signs, falls and insomnia |
| 42218703 | 2026 | Systematic Review | J Cutan Med Surg | Hair loss in patients with ADHD |
| 21586916 | 2011 | Cohort | Clin Neuropharmacol | Preliminary report on methylphenidate in paediatric ADHD with comorbid trichotillomania |
| 24045603 | 2013 | Cohort | Clin Neuropharmacol | Effect of methylphenidate on mood and ADHD symptoms in youths with comorbid subsyndromal depression |
| 41636287 | 2026 | Cohort | Mov Disord Clin Pract | Retrospective questionnaire on stimulant effects on fatigue, alertness and cognition in cerebellar disorders |
| 25976218 | 2015 | Case report | CNS Neurosci Ther | Low-dose methylphenidate for ADHD features secondary to hereditary cerebellar ataxia |
| 16087769 | 2005 | Cohort | Arch Neurol | Dopamine transporter PET in spinocerebellar ataxias types 1, 2, 3 and 6 |
| 28492426 | 2017 | Case report | J Clin Psychopharmacol | Trichotillomania arising in ADHD under methylphenidate treatment |
| 41128391 | 2026 | Cohort | Psychiatry Clin Neurosci | Extended-release methylphenidate effects on dopamine and norepinephrine transporters in adults with ADHD (dual-tracer PET) |
| 29744873 | 2018 | Systematic Review | Cochrane Database Syst Rev | Adverse events of methylphenidate for ADHD in children and adolescents from non-randomised studies |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12116Q | Ritalin LA | Capsule containing methylphenidate hydrochloride 60 mg (modified release) | Not recorded in the data compiled for this report |
Safety Considerations
- Disease contraindications flagged in the knowledge graph (these come from graph relationships, not from product label text): hypertension, epilepsy, bipolar and other major affective disorders, psychotic and schizophrenia-spectrum disorders, substance abuse or dependence, coronary artery disease, stroke and cerebrovascular disorders, myocardial infarction, sudden cardiac arrest, heart conduction disease, anorexia nervosa, glaucoma, hyperthyroidism (including Graves disease and thyrotoxicosis), thrombocytopenia, leukopenia, anaemia and haemoglobinopathy.
- Drug interactions (100 recorded; the main ones are shown):
- Major: bupropion.
- Moderate: isometheptene, ephedrine, epinephrine, and bowel preparations (polyethylene glycol 3350 with electrolytes, picosulfuric acid, sodium sulfate).
- Other recorded interactions (for example doxycycline, metformin, omeprazole, pantoprazole, morphine, simvastatin and prednisone) have an unclassified severity.
- Insomnia is a recognised adverse effect.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The top prediction, faciodigitogenital syndrome, has a very high model score but no trials, no literature and no identifiable mechanistic link, so it is not actionable. None of the other predictions has direct evidence of benefit. Several are mechanistically implausible (insomnia, trichotillomania), or are essentially the approved ADHD use (specific developmental disorder).
To proceed, the following is needed:
- Mechanism of action data for methylphenidate
- TGA Product Information, including approved indications, warnings and contraindications, for the ARTG entry
- For faciodigitogenital syndrome, a defined clinical target (for example ADHD-like symptoms) and supporting clinical or preclinical evidence
- A safety review for any target population, given the cardiovascular, psychiatric and seizure-related contraindication signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.